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fewer Fitbit steps were: non-white race (p = 0.012), high 
school education or less (p = 0.0005), higher body mass 
index (p = 0.0024), and never/almost never drinking alco-
hol (p = 0.0048). Physical activity variables associated with 
greater Fitbit steps were: pre-chemotherapy history of vigor-
ous physical activity (p = 0.0091) and higher self-reported 
walking minutes/week (p < 0.001), and higher outcome 
expectations from exercise (p = 0.014). Higher baseline 
anxiety (p = 0.03) and higher number of chemotherapy-
related symptoms rates “severe/very severe” (p = 0.012) 
were associated with fewer steps. In multivariable analysis, 
white race was associated with 12,146 greater Fitbit steps 
per week (p = 0.004), as was self-reported walking minutes 
prior to start of chemotherapy (p < 0.0001).
Conclusions Inexpensive commercial-grade activity track-
ers, with data uploaded directly into research computers, 
enable objective monitoring of home-based exercise inter-
ventions in adults diagnosed with cancer. Analysis of the 
association of walking steps with participant characteristics 
at baseline and toxicities during chemotherapy can identify 
reasons for low/non-adherence with prescribed exercise 
regimens.
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Introduction
Women diagnosed with breast cancer are often sedentary 
at diagnosis [1, 2] and many reduce their physical activity 
during and after breast cancer treatment [3–5]. Achieving 
and maintaining guideline-recommended levels of physical 
activity (150 min/week) [6, 7] can be especially challenging 
during chemotherapy [8, 9]. Over the past several decades, a 
Abstract 
Purpose Ensuring and measuring adherence to prescribed 
exercise regimens are fundamental challenges in interven-
tion studies to promote exercise in adults with cancer. This 
study reports exercise adherence in women who were asked 
to walk 150 min/week throughout chemotherapy treatment 
for early breast cancer. Participants were asked to wear a 
 FitbitTM throughout their waking hours, and Fitbit steps were 
uploaded directly into study computers.
Methods Descriptive statistics are reported, and both unad-
justed and multivariable linear regression models were used 
to assess associations between participant characteristics, 
breast cancer diagnosis, treatment, chemotherapy toxicities, 
and patient-reported symptoms with average Fitbit steps/
week.
Results Of 127 women consented to the study, 100 had 
analyzable Fitbit data (79%); mean age was 48 and 31% 
were non-white. Mean walking steps were 3956 per day. 
Nineteen percent were fully adherent with the target of 6686 
steps/day and an additional 24% were moderately adherent. 
In unadjusted analysis, baseline variables associated with 
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large and growing number of studies have tested the impact 
of exercise in adults diagnosed with cancer, especially in 
women diagnosed with breast cancer [10, 11]. Most of these 
studies have entailed exercise under supervised conditions, 
at specified times and places and with research staff present 
to ensure fidelity to prescribed exercise regimens. Over the 
past decade, however, there has been growing interest in 
home-based intervention studies, where participants meet 
the study’s exercise requirements at times and places of 
their choosing, and without direct research staff support 
and supervision. For physical activity, as in other behav-
ior modification interventions, encouraging and ensuring 
exercise adherence is a fundamental challenge. In fact, a 
recent Cochrane Review of exercise in women receiving 
adjuvant therapy for breast cancer concluded that in 22 
of the 32 studies included in the review, reported exercise 
adherence was so low that the review authors concluded 
that the results from these studies were at a high risk for 
bias [12]. For home-based intervention studies, an additional 
challenge beyond actual exercise adherence is the measure‑ 
ment of adherence in the absence of supervisory research 
staff to observe participants as they complete their exercise 
regimens.
In lieu of direct observation, one option for independ-
ent assessment of unsupervised activity levels is to ask 
participants to wear an accelerometer that provides highly 
accurate measures of movement duration and intensity [13]. 
Examples of research-grade accelerometers include Acti-
Graph, Actiheart, Actiwatch, GENEActiv, and AticPaL 
[14] which are generally worn for brief observation periods 
of 1 or 2 weeks, although newer technologies using adhe-
sive patches are designed for longer observation. Another 
option is the growing variety of commercially available fit-
ness trackers that are less expensive and comfortable to wear 
over several weeks or months. Examples of these activity 
trackers include products offered by Apple Watch, Fitbit, 
Jawbone, Microsoft Band, Samsung Gear Fit, Garmin, and 
Polar [14–16]. Commercial devices have been strongly vali-
dated as a measure of steps per minute/hour/day [16–18]. An 
important advantage of both research-grade accelerometers 
and commercial-grade fitness trackers is that data collected 
through these devices can be uploaded directly into research 
databases for independent monitoring of participant activ-
ity levels and easy access for data analysis for reports and 
manuscripts [19]. There is a need and an opportunity to 
increase the use of validated activity trackers for independ-
ent assessment of adherence to home-based physical activity 
interventions through direct uploading of tracker data. There 
is also a need for detailed reporting on how adherence is 
defined a priori and measured and for the identification of 
barriers and facilitators to activity adherence.
Here, we report initial findings from a longitudinal, 
observational study of a home-based intervention in women 
diagnosed with early stage breast cancer who were given 
a Fitbit  ZipTM and asked to walk for exercise throughout 
their chemotherapy, with Fitbit data uploaded directly into 
research computers. We provide a priori definition of adher-
ence, and investigate patient level predictors of adherence 
to walking the intervention-required 150 min/week. For our 
analysis, we draw on the Physical Activity Adherence Model 
(PAAM) [20] which posits that baseline physical (age, body 
mass index, breast cancer diagnosis, and treatment), psycho-
logical (anxiety, depression, self-efficacy, outcome expecta-
tions), and social variables (social support, social activity), 
as well as history of previous physical activity, activities of 
daily living, and adverse events during treatment (chemo-
therapy toxicities, patient-reported symptoms) may be pre-
dictive of physical activity adherence during chemotherapy 
treatment.
Participants and methods
This study was reviewed and approved by the University of 
North Carolina (UNC) at Chapel Hill Lineberger Compre-
hensive Cancer Center (LCCC) Protocol Review Committee 
and the UNC Institutional Review Board (IRB).
Study participants
The investigation reported here is part of a larger parent 
study to assess the impact of a walking intervention dur-
ing breast cancer chemotherapy on biomarkers and patient-
reported outcomes (6-month data collection for main results 
is still underway) (NCT02167932). For the parent study, 
we recruited women age 21–64 diagnosed with histologi-
cally confirmed early stage breast cancer (Stage I–III) who 
were about to start adjuvant or neoadjuvant chemotherapy 
(a companion study of breast cancer patients age 65 and 
older is still accruing participants, NCT02328313). There 
were no eligibility restrictions with regard to physical activ-
ity prior to breast cancer diagnosis; patients could be either 
sedentary or active. Research staff asked treating clinicians 
if patients were able to perform moderate-intensity physical 
activity and whether there were any comorbidity that would 
advise against participation in the study. Clinician-approved 
patients were approached during a clinic visit prior to the 
start of chemotherapy, informed of the study, and invited to 
participate by providing written informed consent.
The intervention
All consented patients participated in the same physical 
activity intervention. Participants were asked to walk safely 
and comfortably at a pace that was sustainable throughout 
their chemotherapy treatment, with no specific instructions 
about walking intensity. They were asked to aim for 150 min 
a week in any time increments they preferred (such as 10, 
20, or 30 min at a time). Participants received a Fitbit  ZipTM 
(Fitbit Inc., San Francisco CA) that they were instructed to 
wear during all waking hours. A Fitbit account (www.fitbit.
com) was set up at study enrollment, and Fitbit data was 
uploaded directly into the research database during regu-
larly scheduled chemotherapy treatments. Participants also 
received a 1-page “Walking during Chemotherapy” moti-
vational flyer, a copy of a Walk with Ease workbook [21] 
with tips for starting and sustaining self-directed walking, 
and a printed walking exercise log to record daily minutes 
of walking for leisure, pleasure, or exercise.
Both the Fitbits and walking logs were considered impor-
tant components of the intervention. Participants could see 
their daily activity levels on their Fitbit, which allowed them 
to monitor and self-regulate their physical activity [22]. 
Participants could also self-assess how their activity levels 
affected their quality of life, such as fatigue, sleep quality, 
and joint pain or stiffness. This highly personalized feedback 
was important to the intervention because it can improve the 
study participant’s self-efficacy for exercise [23] and their 
outcome expectations from exercise [24] which, in turn, may 
encourage intervention adherence. Daily activity logs can be 
similarly motivational and educational [25].
Definition of walking adherence
In adult women, 5000 steps per day or 35,000 steps per week 
are considered a sedentary lifestyle [26]. We used this as 
the baseline minimum steps without the additional walk-
ing requested in our intervention. Prior studies of women 
diagnosed with breast cancer have estimated baseline (pre-
treatment) steps ranging from 5437 to 6907 per day [27–29]. 
To estimate the number of steps to achieve the additional 
150 min of walking/week requested for our intervention, 
we assumed a comfortable walking pace for women age 65 
or younger at 60 steps/minute (well below the “moderate” 
walking rate of 100 steps/minute [30]) and multiplied this 
by 150 min to determine 9000 steps/week. Adding sedentary 
lifestyle (35,000 steps/week) to interventional walking (9000 
steps/week), we defined “walking adherence” as 44,000 
steps per week or on average 6286 steps/day.
Measures
Walking activity
Fitbit steps were uploaded during chemotherapy visits and 
summed by week. Self-reported physical activity was also 
collected at baseline (pre-chemotherapy) using two ques-
tions: (1) how many days a week do you go for a walk 
for at least 10 min, for any reason, in and around your 
neighborhood or elsewhere and (2) how much time do you 
usually spend per day when you go for a walk in or around 
your neighborhood or elsewhere. The behavioral risk factor 
surveillance system (BRFSS) health behaviors questionnaire 
[31] was administered at baseline to inquire about engage-
ment in vigorous physical activity for at least 10 min that
causes heavy sweating or large increases in heart rate or
breathing—number of times per week and number of min-
utes each time (this questionnaire also includes items about
smoking history and alcohol use).
Function/physical performance
At baseline, participants were assessed using three meas-
ures: physician-assessed and patient-reported Karnofsky 
performance status (KPS) [32], Timed Up and Go (TUG) 
test [33], and short physical performance battery (SPPB) 
[34], which includes repeated chair stands, balance testing, 
and 8-foot walk to derive a summary score.
Patient‑reported measures
At baseline, participants completed questionnaires pertain-
ing to their quality of life: functional assessment of cancer 
therapy-breast (FACT-B Version 4) [35], functional assess-
ment of chronic illness therapy-fatigue (FACIT-F Version 
4) [36], mental health index-13 (MHI-13) [37], medical out-
comes survey (MOS) physical function [38], instrumental
activities of daily living (IADL) [39], MOS social support
[40], and MOS social activity [41]. Participants also com-
pleted questionnaires pertaining to their outcome expecta-
tions from exercise (OEE) [42] and perceived self-efficacy
for fatigue self-management (PSEFSM) [43].
Chemotherapy toxicities
Research staff reviewed the electronic medical records 
(EMR) of participants throughout their chemotherapy for 
evidence of toxicities including hospitalizations and dose 
delays, dose reductions, and treatment discontinuations. 
Further, at each chemotherapy visit, participants completed 
a patient-reported symptom monitoring (PRSM) form [44] 
to rate their symptoms over the past 7 days as none, mild, 
moderate, severe, or very severe. The PRSM is similar to 
the PRO-CTCAE (patient-reported Common Terminology 
Criteria for Adverse Events/CTCAE) [45, 46], which was 
not available at the time our study was launched.
Medical chart review
EMR were reviewed for data pertaining to breast cancer 
diagnosis and treatment, height, weight, and body mass 
index (BMI).
Demographics
Participants provided information regarding their age, 
race, education, marital status, living arrangements, and 
employment status.
Statistical considerations
Descriptive statistics are reported. Unadjusted linear 
regression models were used to assess the association 
between baseline participant characteristics, breast cancer 
diagnosis, treatment, chemotherapy toxicities, and patient-
reported symptoms with average walking steps/week. For 
each patient, their average Fitbit steps per week were cal-
culated based on total steps divided by weeks receiving 
chemotherapy (range 6–12 weeks). Due to limited sample 
size, covariates for the final multivariable model were cho-
sen based on strength of bivariate association with Fitbit 
steps as well as clinical significance and representation in 
the PAAM conceptual model. All analyses were conducted 
using SAS Version 9.3 (Cary NC).
Results
Study sample
Of 127 women consented to the study, 100 had analyz-
able Fitbit data (79%). Seventeen women were excluded 
from our analysis because they did not have any Fitbit 
data when we attempted to upload data from their Fitbit 
address. Of these 17 women, five nevertheless had well-
maintained printed diaries recording walking minutes per 
day. An additional 10 women were excluded because they 
had 3 weeks or less of Fitbit data. The 27 women who 
were excluded from the final sample were less likely to be 
married (p = 0.01), had lower FACT-G physical wellbeing 
(p = 0.05), and had worse fatigue (p = 0.04). They also 
had more hospitalizations during chemotherapy (p = 0.02) 
and more dose delays (p = 0.03).
Study participant characteristics
Demographics
Baseline characteristics for the final sample (N = 100) are 
presented in Table 1. Mean age was 48 (range 24–64), 31% 
were non-white, 31% had a high school education or less, 
41% were not married, 21% were living alone, and 43% 
were not employed more than 32 h per week. With regard 
to BMI, 30% were normal weight, 34% were overweight, 
and 36% were obese.
Function and lifestyle
At baseline, KPS scores were rated 80 or higher by 100% 
of clinicians and by 87% of participants. Fifteen percent of 
participants required 14 s or more to complete the Timed Up 
and Go test. Mean score on the short physical performance 
battery was 11 (on a scale from 0 to 12). Most participants 
reported never smoking (63%) and never/almost never drink-
ing alcohol (59%). Forty-one percent reported never engag-
ing in vigorous physical activity or doing so only a few times 
a month, and mean self-reported walking minutes per week 
was 133 (range 0–420).
Function
Forty-eight percent of participants scored high on the MOS 
Physical Function scale based on their responses to questions 
pertaining to limitations in walking (one/several blocks, 
more than a mile), climbing stairs (one/several flights), 
bending/kneeling/stooping, bathing/dressing, lifting/carry-
ing groceries, moderate activities (moving a table/pushing a 
vacuum cleaner/bowling/playing golf), and vigorous activi-
ties (running/lifting heavy objects/participating in strenu-
ous sports). Eighty-eight percent scored high in Instrumental 
Activities of Daily Living (IADLs): using the telephone, 
getting to places outside walking distance, shopping for gro-
ceries or clothes, preparing meals, doing housework, taking 
medications, and handling money matters.
Quality of life and self‑efficacy
A minority of participants reported that physical or emo-
tional problems interfered with their social activities (21%), 
or that their emotional support (6%) or tangible support (8%) 
was low. Participants rated their overall quality of life as 
moderately high (FACT-G summary score of 87 on a 0–108 
scale) and their fatigue as moderate (43 on a 0–52 scale). 
On the mental health index, 27% scored depressed and 47% 
scored anxious. Outcome expectations from exercise were 
generally high (4 on a 1–5 scale), as was perceived self-
efficacy for fatigue self-management (7.6 on a 1–10 scale).
Breast cancer diagnosis, treatment, toxicities, 
and symptoms
Thirty percent of participants had Stage 3 breast cancer, 
57% had a mastectomy, 51% received neoadjuvant chemo-
therapy, and 42% were treated with three or four chemother-
apy drugs. Chemotherapy-related toxicities were reflected 
in hospitalizations (18% of participants), dose reductions 
 Table 1  Study participant characteristics 
(N=100)
Variable Mean (SD) or number (percent)
Demographics
 Age 48.3 (SD 9.4) (range 24–64)
 Race
  White 69 (69%)
  African American or other 31 (31%)
 Education
  High school or less 32 (31%)











 Body mass index (BMI) 28.5 (SD 6.1) (range 20–47)
  Normal (18.5–25) 29 (30%)
  Overweight (25–30) 33 (34%)
  Obese I (30–35) 19 (20%)
  Obese II (greater than 35) 15 (16%)
 Karnofsky performance status (KPS 80 or higher)
  Professional KPS 99 (100%)
  Patient KPS 83 (87%)
 Timed up and go test
  Less than 14 s 84 (85%)
  14 s or more 15 (15%)
 Short physical performance battery (SPPB)—summary score (0 = worst to 12 = best performance) 11.0 (SD 1.5) (range 6–12)
Participant reported
 Smoking history
  Never smoked 59 (63%)
  Smoked in the past 24 (26%)
  Current smoker 10 (11%)
 Alcohol use
  No or almost never 56 (59%)
  Yes 39 (41%)
 Health behavior questionnaire (HBQ): vigorous physical activity
  Never or a few times a month 38 (41%)
  1–2 times a week 19 (20%)
  3 or more times a week 36 (39%)
 HBQ: vigorous minutes per week 33.8 (SD 25.3) (range 0–180)
 Total self-reported walking minutes per week for exercise or pleasure 133.1 (SD 107.8) (range 0–420)
 Physical function score (range 0–20) 17.4 (SD 3.7) (range 3–20)
  Lower function (score < 20) 49 (52%)
  High function (score 20) 45 (48%)
 Instrumental activities of daily living (IADL) score (range 0–14) (0 = low function, 14 = high function) 13.8 (SD 0.6) (range 10–14)
  Lower function (score < 14) 11 (12%)
  Higher function (score 14) 84 (88%)
 
Table 1  (continued)
Variable Mean (SD) or number (percent)
 Social activity limit score (range 0–100) 65.1 (SD 17.8) (range 25–100)
  Lower social activity (score < 50) 20 (21%)
  Higher social activity (score 50 or higher) 75 (79%)
 Social support-emotional score (range 0–100) 88.2 (SD 21.2) (range 3–100)
  Lower social support (score < 50) 6 (6%)
  Higher social support (score 50 or higher) 89 (94%)
 Social support-tangible score (range 0–100) 86.0 (SD 22.5) (range 6–100)
  Lower social support (score < 50) 8 (8%)
  Higher social support (score 50 or higher) 87 (92%)
 Functional assessment of cancer therapy-general (FACT-G) composite score (range 0–108) (higher 
score = higher wellbeing)
87.1 (SD 15.5) (range 36–108)
  FACT-G physical wellbeing (range 0–28) 24.6 (SD 4.1) (range 11–28)
  FACT-G social/family wellbeing (range 0–28) 23.8 (SD 5.4) (range 4–28)
  FACT-G emotional wellbeing (range 0–24) 18.7 (SD 4.2) (range 1–24)
  FACT-G functional wellbeing (range 0–28) 20.0 (SD 6.0) (range 0–28)
 FACIT-fatigue (range 0–52) (reverse scored so that higher score = lower fatigue) 43.3 (SD 8.7) (range 14–52)
 Composite FACT-G/FACIT-fatigue score (range 0–160) 130.4 (SD 22.8) (range 63.6–160)
 Mental health index (MHI)-depressed (range 0–43) 8.7 (SD 7.3) (range 0–35)
  Less depressed (score < 12) 67 (73%)
  More depressed (score = or > 12) 25 (27%)
 Mental health index (MHI)-anxious (range 0–20) 6.0 (SD 3.7) (range 0–16)
  Less anxious (score < 6) 50 (53%)
  More anxious (score = > 6) 44 (47%)
 Outcome expectations from exercise scale (range 1–5) (higher score = higher expectations) 4.2 (SD 0.9) (range 1–5)
 Perceived self-efficacy for fatigue self-management scale (range 1–10) (higher score = higher efficacy) 7.6 (SD 2.1) (range 1–10)












 Total number of chemotherapy drugs taken
  1 or 2 drugs 58 (58%)
  3 or 4 drugs 42 (42%)
 Hospitalized during chemotherapy 18 (18%)
 Dose reduction during chemotherapy 34 (34%)
 Dose delay during chemotherapy 22 (22%)
 Dose discontinuation of chemotherapy 15 (15%)




   Severe, very severe 13%
 Table 1  (continued)












   Severe, very severe 2%
  Fatigue, lack of energy
   None, mild 39%
   Moderate 45%








   Severe, very severe 7%
  Tingling, numbness in hands, feet
   None, mild 81%
   Moderate 15%












   Severe, very severe 17%
 Total number of PRSM systems that were “moderate, sometimes” during chemotherapy
  0 symptoms 22 (22%)
  1–2 symptoms 30 (30%)
  3–4 symptoms 26 (26%)
  Greater than 4 symptoms 22 (22%)
 Total number of PRSM systems that were “severe/very severe, quite a bit/very much, most/all of the time” during chemotherapy
  0 symptoms 20 (20%)
  1–2 symptoms 24 (24%)
  3–4 symptoms 18 (18%)
  Greater than 4 symptoms 38 (38%)
(34%), dose delays (22%), and dose discontinuations (15%). 
Patent-reported symptoms reported during chemotherapy 
treatment as “severe/very severe”, “quite a bit/very much” 
or “most/all of the time” included insomnia (17%), fatigue 
(16%), constipation (11%), and anxiety (11%). Eighteen per-
cent of patients reported 3–4 symptoms and 38% reported 
more than four symptoms as “severe/very severe”, “quite a 
bit/very much”, or “most/all of the time”.
Walking adherence
Mean Fitbit steps per week during chemotherapy were 
27,689 (SD 18,767) or 3956 per day. Fitbit steps per week 
over 12 weeks of chemotherapy are plotted and summarized 
in Fig. 1 as box-and-whisker plots in which the 25th, 50th 
(median), and 75th percentile are marked by the bottom, 
middle, top sides of the box, respectively. The whiskers 
extend out a maximum of 1.5 times the interquartile range 
(75th to 25th percentile). Using the a priori standard of 
44,000 steps per week or 6286 steps per day, only 19% of 
participants were fully adherent with the a priori exercise 
target (Fig. 2). An additional 24% were moderately adherent 
(4000–6000 steps/day). 
Associations with fitbit walking steps
Table 2 presents unadjusted associations between baseline 
characteristics of participants, breast cancer diagnosis and 
treatment, and chemotherapy-related toxicities (events and 
symptoms) with average Fitbit steps per week. Baseline 
variables associated with fewer Fitbit steps were non-white 
race (p = 0.012), having a high school education or less 
Fig. 1  Average Fitbit steps per 
week during chemotherapy (red 
line is target of 44,000 steps/
week)
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Table 2  Unadjusted analysis of associations with mean walking steps per week (N=100)
Variable Estimate p value
Demographics
 Age 322.7 (SE 198.4) 0.107
 Race (White is referent)
  African American or other − 10099.9 (SE (3948.8) 0.012
 Education (more than high school is referent)
  High school or less − 14092.8 (SE 3918.8) 0.0005
 Married (yes is referent)
  No − 7452.8 (SE 3904.4) 0.059
 Living alone (yes is referent)
  No − 424.0 (SE 5493.0) 0.939
 Employed > 32 h/week (yes if referent)
  No 3846.8 (SE 4342.4) 0.378
Research staff assessed
 Body mass index (BMI) − 952.2 (SE 304.6) 0.0024
 Short physical performance battery (SPPB) 89.1 (SE 1425.6) 0.950
Participant reported
 Smoking history (current/past is referent)
  Never smoked 1106.8 (SE 4137.7) 0.790
 Alcohol use (yes is referent)
  No/almost never − 11070.9 (SE 3830.1) 0.0048
 Health behavior questionnaire (HBQ): vigorous physical activity (never/few times is referent)*
  At least once a week 10424.8 (SE 3908.9) 0.0091
 Walking minutes per week 79.9 (SE 16.7) < 0.0001
 Physical function score 1310.9 (SE 516.1) 0.013
 Instrumental activities of daily living (IADL) 4395.7 (SE 3065.0) 0.155
 Social activity limitation score 206.2 (SE 108.9) 0.061
 Social support-emotional score 126.1 (SE 92.6) 0.177
 Social support-tangible score 68.2 (SE 87.8) 0.439
 Functional assessment of cancer therapy-general (FACT-G) 287.8 (SE 121.2) 0.020
  FACT-G physical wellbeing 1193.1 (SE 454.3) 0.010
  FACT-G social/family wellbeing 509.1 (SE 352.3) 0.152
  FACT-G emotional wellbeing 259.8 (SE 458.3) 0.572
  FACT-G functional wellbeing 828.0 (SE 313.5) 0.010
 FACIT-fatigue 773.8 (SE 207.4) 0.0003
 FACT-G/FACIT-fatigue total score 245.9 (SE 81.0) 0.0031
 Mental health index (MHI)-depressed − 450.9 (274.8) 0.104
 Mental health index (MHI)-anxious − 1154.5 (SE 524.0) 0.030
 Outcome expectations from exercise scale 4978.0 (SE 1996.5) 0.014
 Perceived self-efficacy for fatigue self-management scale 290.6 (SE 971.9) 0.766
Breast cancer diagnosis, treatment, chemotherapy events, symptoms
 Breast cancer stage (stage III is referent)
  I − 3223.9 (SE 5674.2) 0.571
  II 3368.8 (SE 4413.8) 0.447
 Breast cancer surgery prior to chemotherapy (none is referent)
  Lumpectomy 10147.7 (SE 19156.0) 0.868
  Mastectomy 10083.8 (SE 19097.3)
 Chemotherapy (neoadjuvant is referent)
  Adjuvant − 1431.6 (SE 3770.5) 0.705
 Total number of chemotherapy drugs − 34.5 (SE 2699.1) 0.990
 Duration of chemotherapy treatment − 26.5 (SE 501.3) 0.958
(p = 0.0005), higher Body Mass Index (p = 0.0024), and 
never/almost never drinking alcohol (p = 0.0048). Physical 
activity variables associated with greater Fitbit steps dur-
ing chemotherapy were history of vigorous physical activity 
(p = 0.0091), higher self-reported walking minutes/week 
(p < 0.001) prior to chemotherapy, and higher outcome 
expectations from exercise (p = 0.014). 
Higher baseline values in the following measures 
(where higher scores indicate higher quality of life) were 
correlated with greater Fitbit steps during chemotherapy: 
physical function score (p = 0.013), overall FACT-G Score 
(p  =  0.020), FACT-G/Physical Wellbeing (p  =  0.010), 
FACT-G/Functional Wellbeing (p = 0.010), FACIT-fatigue 
(p = 0.0003), and overall quality of life (FACT-G/FACIT-
fatigue) (p = 0.0031). Higher anxiety as measured by the 
MHI Anxiety score was inversely associated with Fitbit steps 
(p = 0.03). A higher number of chemotherapy-related symp-
toms reported as “severe/very severe” was also associated 
with fewer Fitbit steps (p = 0.012).
To create a parsimonious model for our limited sam-
ple, the multivariable model (Table  3) was limited to 
variables that were highly significant at p < 0.01 in unad-
justed analysis and measured different domains: race, 
education, BMI, total score for FACT-G/FACIT-fatigue, 
outcome expectations from exercise, PRSM symptom 
“severe/very severe”, and self-reported walking minutes/
week at baseline. In this model, white race was associ-
ated with 12,146 greater Fitbit steps per week on average 
(p = 0.004) after adjustment for other variables. Similarly, 
self-reported walking minutes prior to chemotherapy was 
associated with increased Fitbit steps during chemotherapy 
(p < 0.0001); for every 30 min of increased self-reported 
walking minutes at baseline, average Fitbit steps per week 
during chemotherapy increased by 2370 (30 min times 79). 
The amount of variance in Fitbit steps/week explained by 
the model was 36% (adjusted R-square = 0.36).
Table 2  (continued)
Variable Estimate p value
 Chemotherapy dose frequency 1373.3 (SE 2107.1) 0.516
 Hospitalized during chemotherapy (yes is referent) 0.751
  No 1561.2 (SE 4907.2)
 Dose reduction during chemotherapy (yes is referent)
  No 7264.5 (SE 3913.7) 0.066
 Dose delay during chemotherapy (yes is referent)
  No 4751.8 (SE 4528.1) 0.297
 Dose discontinuation of chemotherapy (yes is referent)
  No 7241.9 (SE 5231.7) 0.169
 Total number of PRSM symptoms that were “moderate, sometimes” during chemotherapy − 259.3 (SE 850.2) 0.761
 Total number of PRSM symptoms that were “severe/very severe” during chemotherapy − 2859.4 (SE 1117.9) 0.012
Bold print identifies p values that are significant (p < 0.05)
PRSM patient-reported symptom monitoring
Table 3  Multivariable 
analysis of associations with 
mean walking steps per week 
(N = 100)
Bold print identifies p values that are significant (p < 0.05)
Model: p < 0.0001
Adjusted R-squared = 0.36
Variable Estimate p value
Race: white 12146 (SE 4120.5) 0.004
Education 6236.6 (SE 4060.7) 0.129
Body mass index − 267.1 (SE 312.8) 0.396
Total FACT-G/FACIT-F score 96.7 (SE 97.5) 0.324
Outcome expectations from exercise 389.4 (SE 1950.0) 0.842
Total number of chemotherapy-related symptoms patient-
reported as “severe/very severe”
6236.6 (SE 4060.7) 0.129
Self-reported walking minutes/week at baseline 79.0 (SE 17.3) < 0.0001
Discussion
In this home-based exercise intervention, women with early 
stage breast cancer were asked to walk 150 min a week 
throughout their chemotherapy treatment and to wear a Fit-
bit during their waking hours. Intervention implementation 
appeared feasible, with 79% of participants having analyz-
able Fitbit data; however, full intervention adherence was 
observed in only 19% of participants. In multivariable analy-
sis limited to variables that were highly significant (p < 0.01) 
in unadjusted analyses and representing different domains, 
white race and higher number of self-reported walking min-
utes/week prior to start of chemotherapy were significant 
predictors of greater Fitbit steps during chemotherapy.
Our study contributes to the literature pertaining to 
home-based exercise interventions in breast cancer patients 
undergoing chemotherapy by defining exercise adherence, 
a priori and analyzing adherence using Fitbit data that were 
uploaded directly into research computers. Adherence to a 
study’s administrative requirements is important to report, 
such as the proportion of participants who completed ques-
tionnaires and diaries. However, the assessment of exer‑ 
cise impact on primary and secondary outcomes requires 
measures of actual exercise throughout the study period. In 
this regard, our study points to the advantages of independ-
ent measurement of exercise adherence through the use of 
commercially available activity trackers. To date, only a few 
studies of home-based exercise interventions in breast can-
cer patients have included pedometers or activity trackers 
that are worn throughout chemotherapy. Of these studies, 
four measured exercise adherence based on participant self-
report of walking steps [20, 27, 47, 48] and only one study 
directly uploaded pedometer or tracker steps into study com-
puters [49]. All of these studies have small sample sizes, 
while our study was conducted in a relatively larger sample 
of women (N = 100).
The average of 3956 steps per day reported in our study is 
below the average steps reported in other intervention stud-
ies of women walking throughout 10–12 weeks of chemo-
therapy for early breast cancer [47, 49]. Our intervention was 
selected because it requires minimal staff and oversight, to 
mirror as closely as possible what could be feasible during a 
busy clinic visit—guidance and motivational materials at the 
onset of chemotherapy and minimal interactions with par-
ticipants when Fitbit data were uploaded during chemother-
apy visits. We found that reasons for sub-optimal walking 
were not related to breast cancer treatment, adverse events, 
or patient-reported symptoms. Instead, it is likely that our 
minimalist intervention was not sufficiently motivational for 
some participants to encourage them to make an extra effort 
to walk throughout chemotherapy or there were other barri-
ers to their exercise adherence [25, 50–52]. Or, some partici-
pants may not have worn their Fitbit throughout their waking 
hours. For future low-intensity interventions, we would 
consider targeting patient groups who were least likely to 
achieve the walking goal, including non-white women and 
those with low levels of baseline physical activity, for more 
intensive assistance and encouragement to walk through-
out chemotherapy. We would also consider including brief, 
semi-structured motivational conversations with participants 
when Fitbit data are uploaded during chemotherapy visits, 
and instructions to focus on achieving steps per day rather 
than just walking minutes per week. Nevertheless, our study 
demonstrates that for some patient groups, a low-intensity 
intervention may be sufficient to encourage maintenance of 
physical activity during the chemotherapy period [50, 53]. 
Our finding of the positive influence of exercise history prior 
to treatment has been observed in other studies as well [9, 
20, 54]; women who were exercising prior to their breast 
cancer diagnosis are more likely to continue exercising dur-
ing treatment.
It is a limitation of our study that we did not check the 
uploaded Fitbit data until all participants had completed 
their chemotherapy. If we had checked the data periodi-
cally throughout chemotherapy, we would have identified 
participants without Fitbit data and investigated possible 
reasons. For example, the five participants who maintained 
printed exercise logs but did not have Fitbit data would sug-
gest a tracker malfunction rather than a deliberate decision 
not to wear a Fitbit. Periodic checking of Fitbit data would 
also identify participants who were not wearing their Fitbit 
throughout their waking hours, thereby contributing to the 
low average Fitbit steps observed in our study. It would also 
have been an improvement on the study if a post-chemo-
therapy survey had inquired about barriers and facilitators 
to wearing a Fitbit throughout their waking hours.
Our study suggests that wearing an activity tracker 
throughout chemotherapy is feasible and acceptable [55]. 
The activity tracker can provide real-time feedback that may 
increase physical activity self-awareness, self-regulation, 
and self-monitoring [15, 55, 56]. The growing availability 
of relatively inexpensive commercially available activity 
trackers to collect 24-7 data that can be directly accessed 
by study investigators provides an important opportunity 
for home-based intervention studies to include independent 
assessments of physical activity adherence. Low-cost track-
ers worn over extended periods also present an opportunity 
for an evolving area of research focused on the interface 
of physical activity and on-going monitoring of patient-
centered symptoms and outcomes during active treatment 
for a variety of cancer diagnoses [57]. This is an evolving 
area of research, but there is already promising evidence of 
the value of attention to physical activity in making objec-
tive estimates of treatment-related symptoms and declines 
in function and quality of life, in addition to or in lieu of 
patient-reported outcomes [57–61].
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